Eli Lil­ly is now the sec­ond drug­mak­er to pro­pose a re­bate mod­el for 340B drug price dis­counts — and the sec­ond to ...

The European Medicines Agency has flipped its stance on Eisai and Biogen’s Alzheimer’s treatment Leqembi, recommending ...

Merz Therapeutics landed in hot water last month when the FDA said a social media promotion for its Botox rival Xeomin was ...

More cuts are hitting Gilead’s cell therapy wing, including the closure of a Philadelphia office. A small number of ...

Sen. Bill Cassidy (R-LA) will take over the Senate Health, Education, Labor, and Pensions Committee when the GOP gets control ...

The Eu­ro­pean Com­mis­sion is ask­ing bio­phar­ma and man­u­fac­tur­ing com­pa­nies about their re­ac­tion to No­vo ...

New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.

Summit Therapeutics and its Chinese partner Akeso have a few competitors now. Merck, the maker of the drug they're trying to ...

No­vo Nordisk said Thurs­day that it plans to even­tu­al­ly halt all of its hu­man in­sulin pen pro­duc­tion glob­al­ly, ...

Bluebird reports 17 people with sickle cell disease started receiving Lyfgenia gene therapy, with 35 starting Zynteglo for ...

Ascidian Therapeutics CEO Michael Ehlers is leaving the venture investor that serves as his home base and will join MPM ...

The global pharma company whose name rhymes with the capital of China wants people to know that it is not in fact a Chinese ...